Effects of orally taken kallidinogenase on retinal blood flow among patients with central retinal vein occlusion (CRVO)

Effects of orally taken kallidinogenase on retinal blood flow among patients with central retinal vein occlusion (CRVO) - Effects of orally taken kallidinogenase on retinal blood flow among patients with central retinal vein occlusion (CRVO)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019036

Enrollment

Registered

2015-09-16

Start date

2015-07-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular edema associated with CRVO

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria are included in this study. 1. At 20 years of age or older 2. Male or female 3. Treated with anti VEGF for a year or longer at our hospital (Nagasaki University Hospital) 4. The first anti VEGF treatment at our hospital was between June, 2010 and June, 30, 2014

Exclusion criteria

Exclusion criteria: Patients who fall into any of the following criteria are excluded from participating in the study. 1. Anti VEGF treatment at our hospital lasts less than a year 2. Ischemic CRVO 3. Others whom an investigator determined to be inappropriate to include in the study

Design outcomes

Primary

Measure	Time frame
Change in volume of retinal blood flow from pretreatment to a month after the final treatment or to the last visit	—

Countries

Japan

Contacts

Public ContactMakiko Matsumoto , Fumito Akiyama

Nagasaki University Graduate School of Biomedical Sciences Department of Ophthalmology and Visual Sciences

makimaki@nagasaki-u.ac.jp095-819-7345

Outcome results